CRISPR Therapeutics (CRSP) Short Interest Ratio & Short Volume $37.73 -0.94 (-2.43%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$37.76 +0.03 (+0.08%) As of 04:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRISPR Therapeutics Short Interest DataCRISPR Therapeutics (CRSP) has a short interest of 20.76 million shares, representing 25.24% of the float (the number of shares available for trading by the public). This marks a 1.22% increase in short interest from the previous month. The short interest ratio (days to cover) is 9.3, indicating that it would take 9.3 days of the average trading volume of 1.64 million shares to cover all short positions.Current Short Interest20,760,000 sharesPrevious Short Interest20,510,000 sharesChange Vs. Previous Month+1.22%Dollar Volume Sold Short$808.60 millionShort Interest Ratio9.3 Days to CoverLast Record DateApril 15, 2025Outstanding Shares86,363,000 sharesShort Percent of Float25.24%Today's Trading Volume1,937,575 sharesAverage Trading Volume1,639,894 sharesToday's Volume Vs. Average118% Short Selling CRISPR Therapeutics? Sign up to receive the latest short interest report for CRISPR Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCRSP Short Interest Over TimeCRSP Days to Cover Over TimeCRSP Percentage of Float Shorted Over Time CRISPR Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202520,760,000 shares $808.60 million +1.2%25.2%9.3 $38.95 3/31/202520,510,000 shares $697.96 million +1.0%24.9%9.2 $34.03 3/15/202520,310,000 shares $855.46 million -2.4%24.7%9.7 $42.12 2/28/202520,810,000 shares $913.98 million +2.0%25.3%9.7 $43.92 2/15/202520,410,000 shares $1.01 billion +4.7%24.8%9.5 $49.72 1/31/202519,490,000 shares $810.59 million -4.0%N/A10.1 $41.59 1/15/202520,310,000 shares $792.90 million +6.3%N/A10.8 $39.04 12/31/202419,100,000 shares $751.78 million +5.4%N/A11.4 $39.36 12/15/202418,120,000 shares $793.29 million -0.2%N/A11.6 $43.78 11/30/202418,150,000 shares $928.74 million -6.4%N/A12.7 $51.17 Get the Latest News and Ratings for CRSP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/202419,390,000 shares $916.18 million +4.3%N/A14.8 $47.25 10/31/202418,590,000 shares $862.39 million +5.7%N/A16 $46.39 10/15/202417,590,000 shares $845.20 million +0.2%N/A16.1 $48.05 9/30/202417,560,000 shares $824.97 million +0.1%N/A14.9 $46.98 9/15/202417,540,000 shares $858.41 million +0.6%N/A14.7 $48.94 8/31/202417,440,000 shares $832.24 million +1.6%N/A13.8 $47.72 8/15/202417,170,000 shares $838.75 million +4.5%N/A13.1 $48.85 7/31/202416,430,000 shares $941.27 million +1.9%N/A12 $57.29 7/15/202416,120,000 shares $926.26 million +3.0%N/A12 $57.46 6/30/202415,650,000 shares $845.26 million +5.3%N/A11.9 $54.01 6/15/202414,870,000 shares $945.14 million -5.0%N/A11.1 $63.56 5/31/202415,660,000 shares $841.57 million +2.2%N/A12 $53.74 5/15/202415,330,000 shares $873.20 million +5.1%N/A10.9 $56.96 4/30/202414,590,000 shares $773.12 million -1.0%N/A8.5 $52.99 4/15/202414,740,000 shares $865.53 million -0.1%N/A8.5 $58.72 3/31/202414,760,000 shares $1.01 billion +0.3%N/A7.9 $68.16 3/15/202414,720,000 shares $1.07 billion -2.3%N/A7.4 $72.95 2/29/202415,060,000 shares $1.27 billion +1.3%N/A5.8 $84.22 2/15/202414,870,000 shares $1.26 billion -5.5%N/A5.5 $84.48 1/31/202415,740,000 shares $990.83 million -7.6%N/A5.6 $62.95 1/15/202417,040,000 shares $1.09 billion +4.9%N/A5.8 $64.25 12/31/202316,250,000 shares $1.02 billion -6.2%N/A5.9 $62.60 12/15/202317,330,000 shares $1.08 billion +8.8%N/A6.6 $62.08 11/30/202315,930,000 shares $1.06 billion -2.7%N/A7 $66.73 11/15/202316,370,000 shares $920.49 million +17.9%N/A9.6 $56.23 10/31/202313,890,000 shares $540.74 million +2.5%N/A10.9 $38.93 10/15/202313,550,000 shares $600.40 million +3.9%N/A13.3 $44.31 9/30/202313,040,000 shares $591.89 million -5.4%N/A13.4 $45.39 9/15/202313,790,000 shares $697.50 million -2.1%N/A14.6 $50.58 8/31/202314,080,000 shares $704.14 million +5.0%N/A13.7 $50.01Buffett’s favorite chart just hit 209% – here’s what that means for gold (Ad)A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.Be ready before the historic gold move. Get Garrett’s Top Four picks now. 8/15/202313,410,000 shares $652.80 million +10.7%N/A11.9 $48.68 7/31/202312,110,000 shares $694.27 million -1.6%N/A9.5 $57.33 7/15/202312,310,000 shares $700.56 million -2.1%N/A9.8 $56.91 6/30/202312,570,000 shares $705.68 million +0.8%16.6%9.2 $56.14 6/15/202312,470,000 shares $734.98 million +2.3%16.5%9 $58.94 5/31/202312,190,000 shares $780.65 million -1.9%16.1%9.1 $64.04 5/15/202312,430,000 shares $819.76 million -5.8%16.4%9.5 $65.95 4/30/202313,200,000 shares $646.01 million +1.9%17.5%11.1 $48.94 4/15/202312,950,000 shares $651.51 million +2.0%17.2%11.3 $50.31 3/31/202312,700,000 shares $574.42 million +4.3%16.9%12.2 $45.23 3/15/202312,180,000 shares $547.13 million +9.0%16.2%11.3 $44.92 2/28/202311,170,000 shares $550.90 million +9.0%14.8%10 $49.32 2/15/202310,250,000 shares $534.74 million +2.7%13.7%9.4 $52.17 1/31/20239,980,000 shares $509.18 million +1.0%13.3%9.2 $51.02 1/15/20239,880,000 shares $493.41 million -5.7%13.2%9.1 $49.94 12/30/202210,480,000 shares $426.01 million +12.2%14.0%9.9 $40.65 12/15/20229,340,000 shares $443.65 million -16.2%12.4%8.8 $47.50 11/30/202211,140,000 shares $610.36 million -4.3%14.8%10.6 $54.79 11/15/202211,640,000 shares $710.16 million -7.3%15.5%10.8 $61.01 10/31/202212,550,000 shares $656.87 million +6.7%16.7%11.4 $52.34 10/15/202211,760,000 shares $635.86 million +1.7%15.7%10.4 $54.07 9/30/202211,560,000 shares $755.45 million +5.8%16.1%9.1 $65.35 9/15/202210,930,000 shares $819.86 million +0.5%15.3%7.5 $75.01 8/31/202210,880,000 shares $708.18 million +1.5%15.2%6 $65.09 8/15/202210,720,000 shares $859.10 million -2.3%15.0%5.7 $80.14 7/31/202210,970,000 shares $822.75 million -4.9%15.4%5.5 $75.00 7/15/202211,530,000 shares $961.49 million +1.9%16.2%5.8 $83.39 6/30/202211,320,000 shares $687.92 million +6.4%15.9%6.1 $60.77 6/15/202210,640,000 shares $666.70 million +4.0%15.0%6.3 $62.66 5/31/202210,230,000 shares $593.85 million -7.2%14.4%7.3 $58.05 5/15/202211,020,000 shares $575.57 million +8.7%15.5%7.7 $52.23 4/30/202210,140,000 shares $503.15 million -2.3%14.3%7.1 $49.62 4/15/202210,380,000 shares $645.53 million +3.3%14.7%6.8 $62.19 3/31/202210,050,000 shares $630.84 million +7.0%14.2%6.2 $62.77 3/15/20229,390,000 shares $563.78 million +2.5%13.3%5.6 $60.04 2/28/20229,160,000 shares $562.15 million +4.9%13.0%5.5 $61.37 2/15/20228,730,000 shares $532.27 million +6.5%12.4%5.2 $60.97 1/31/20228,200,000 shares $522.75 million -4.0%11.8%5 $63.75 1/15/20228,540,000 shares $578.76 million +6.1%N/A0 $67.77 12/31/20218,050,000 shares $610.03 million -1.2%11.6%4.9 $75.78 12/15/20218,150,000 shares $642.79 million +17.4%11.7%5.1 $78.87 11/30/20216,940,000 shares $554.51 million +18.6%10.0%4.8 $79.90 11/15/20215,850,000 shares $497.72 million +4.8%8.4%4.4 $85.08 10/29/20215,580,000 shares $509.62 million +15.8%8.0%4.4 $91.33 10/15/20214,820,000 shares $467.54 million +80.5%6.9%3.8 $97.00 9/30/20212,670,000 shares $298.85 million -15.8%3.8%2.4 $111.93 9/15/20213,170,000 shares $371.71 million +7.1%4.6%2.6 $117.26 8/31/20212,960,000 shares $369.85 million +0.7%4.4%2.4 $124.95 8/13/20212,940,000 shares $372.67 million +14.0%4.6%2.3 $126.76 7/30/20212,580,000 shares $312.23 million +11.2%4.1%1.9 $121.02Buffett’s favorite chart just hit 209% – here’s what that means for gold (Ad)A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.Be ready before the historic gold move. Get Garrett’s Top Four picks now. 7/15/20212,320,000 shares $294.87 million -28.0%3.6%1.7 $127.10 6/30/20213,220,000 shares $521.29 million -4.2%5.0%2.2 $161.89 6/15/20213,360,000 shares $415.36 million +1.2%5.4%2.6 $123.62 5/28/20213,320,000 shares $392.36 million -14.2%5.3%2.4 $118.18 5/14/20213,870,000 shares $390.87 million +11.9%N/A2.2 $101.00 4/30/20213,460,000 shares $456.30 million -18.6%N/A1.8 $131.88 4/15/20214,250,000 shares $523.22 million -4.7%N/A2.1 $123.11 3/31/20214,460,000 shares $513.79 million +5.7%N/A2 $115.20 3/15/20214,220,000 shares $551.17 million +12.5%N/A1.7 $130.61 2/26/20213,750,000 shares $477.30 million +23.0%N/A1.5 $127.28 2/12/20213,050,000 shares $485.10 million +3.4%N/A1.4 $159.05 1/29/20212,950,000 shares $493.89 million -19.0%N/A1.5 $167.42 1/15/20213,640,000 shares $764.55 million -5.9%N/A2 $210.04 12/31/20203,870,000 shares $625.28 million +7.2%N/A2.3 $161.57 12/15/20203,610,000 shares $541.72 million -16.2%N/A2.7 $150.06 11/30/20204,310,000 shares $523.88 million -8.1%N/A4 $121.55 11/15/20204,690,000 shares $487.57 million -25.9%N/A5.2 $103.96 10/30/20206,330,000 shares $609.90 million +19.7%N/A6.5 $96.35 10/15/20205,290,000 shares $536.25 million +10.0%9.8%5.5 $101.37 9/30/20204,810,000 shares $402.31 million +2.8%8.9%5.6 $83.64 9/15/20204,680,000 shares $397.47 million +4.9%8.7%4.8 $84.93 8/31/20204,460,000 shares $416.83 million -1.6%8.3%4.3 $93.46 8/14/20204,530,000 shares $405.44 million +4.9%8.4%4.2 $89.50 7/31/20204,320,000 shares $369.19 million +45.5%8.1%4 $85.46 7/15/20202,970,000 shares $277.16 million -28.3%5.7%2.8 $93.32 6/30/20204,140,000 shares $304.25 million +7.8%8.3%3.9 $73.49 6/15/20203,840,000 shares $239.81 million -1.3%8.7%4.2 $62.45 5/29/20203,890,000 shares $251.22 million -8.9%8.8%4.2 $64.58 5/15/20204,270,000 shares $260.85 million +6.2%9.7%4.4 $61.09 CRSP Short Interest - Frequently Asked Questions What is CRISPR Therapeutics' current short interest? Short interest is the volume of CRISPR Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 20,760,000 shares of CRSP short. 25.24% of CRISPR Therapeutics' shares are currently sold short. Learn More on CRISPR Therapeutics' current short interest. What is a good short interest ratio for CRISPR Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CRSP shares currently have a short interest ratio of 9.0. Learn More on CRISPR Therapeutics's short interest ratio. Which institutional investors are shorting CRISPR Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of CRISPR Therapeutics: FNY Investment Advisers LLC, IMC Chicago LLC, GTS Securities LLC, Wolverine Trading LLC, Squarepoint Ops LLC, Group One Trading LLC, Caption Management LLC, Citadel Advisors LLC, Jane Street Group LLC, Tudor Investment Corp ET AL, Two Sigma Securities LLC, Concourse Financial Group Securities Inc., PEAK6 LLC, Walleye Trading LLC, Walleye Capital LLC, Capital Fund Management S.A., One River Asset Management LLC, Eagle Health Investments LP, JPMorgan Chase & Co., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for CRISPR Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 25.24% of CRISPR Therapeutics' floating shares are currently sold short. Is CRISPR Therapeutics' short interest increasing or decreasing? CRISPR Therapeutics saw a increase in short interest in April. As of April 15th, there was short interest totaling 20,760,000 shares, an increase of 1.2% from the previous total of 20,510,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does CRISPR Therapeutics' short interest compare to its competitors? 25.24% of CRISPR Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to CRISPR Therapeutics: Moderna, Inc. (16.48%), Exelixis, Inc. (6.85%), Neurocrine Biosciences, Inc. (4.58%), Qiagen (2.11%), Repligen Co. (6.11%), Bio-Techne Co. (4.25%), Revolution Medicines, Inc. (10.62%), Halozyme Therapeutics, Inc. (7.87%), ADMA Biologics, Inc. (5.82%), Krystal Biotech, Inc. (9.80%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks. What does it mean to sell short CRISPR Therapeutics stock? Short selling CRSP is an investing strategy that aims to generate trading profit from CRISPR Therapeutics as its price is falling. CRSP shares are trading down $0.94 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against CRISPR Therapeutics? A short squeeze for CRISPR Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CRSP, which in turn drives the price of the stock up even further. How often is CRISPR Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CRSP, twice per month. The most recent reporting period available is April, 15 2025. More Short Interest Resources from MarketBeat Related Companies Moderna Short Interest Exelixis Short Interest Neurocrine Biosciences Short Interest Qiagen Short Interest Repligen Short Interest Bio-Techne Short Interest Revolution Medicines Short Interest Halozyme Therapeutics Short Interest ADMA Biologics Short Interest Krystal Biotech Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CRSP) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRSP Stock Free CRSP Stock Alerts